Matt Hitchings

Matt Hitchings,

Assistant Professor

Department: PHHP-COM BIOSTATISTICS
Business Phone: (352) 294-1945
Business Email: mhitchings@ufl.edu

Teaching Profile

Courses Taught
2021-2022,2024
PHC6059 Introduction to Applied Survival Analysis
2023-2024
PHC6937 Special Topics in Public Health
2023-2024
PHC6905 Independent Study
2023-2024
PHC7979 Advanced Research

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-2327-3557

Areas of Interest
  • Clinical Trials Design & Analysis
  • Emerging infectious disease
  • Infectious Diesease
  • Vaccination

Publications

2024
Confronting Health Misinformation Surrounding COVID-19 Vaccines in the State of Florida.
Journal of general internal medicine. [DOI] 10.1007/s11606-024-08726-6. [PMID] 38499724.
2024
Correction: Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial.
PLoS medicine. 21(3) [DOI] 10.1371/journal.pmed.1004370. [PMID] 38507664.
2024
Corrigendum to “Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey” [International Journal of Infectious Diseases 139 (2024) 159-167].
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 141 [DOI] 10.1016/j.ijid.2024.02.007. [PMID] 38452689.
2024
Extensive transmission of SARS-CoV-2 BQ.1* variant in a population with high levels of hybrid immunity: A prevalence survey
International Journal of Infectious Diseases. 139:159-167 [DOI] 10.1016/j.ijid.2023.11.039. [PMID] 38070701.
2024
Overestimation of Severe Acute Respiratory Syndrome Coronavirus 2 Household Transmission in Settings of High Community Transmission: Insights From an Informal Settlement Community in Salvador, Brazil
Open Forum Infectious Diseases. 11(3) [DOI] 10.1093/ofid/ofae065. [PMID] 38516384.
2023
A Mixture Model for Estimating SARS-CoV-2 Seroprevalence in Chennai, India.
American journal of epidemiology. 192(9):1552-1561 [DOI] 10.1093/aje/kwad103. [PMID] 37084085.
2023
Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.
Nature Communications. 14(1) [DOI] 10.1038/s41467-023-37944-5. [PMID] 37076502.
2023
Dynamics of Anti-influenza Mucosal IgA Over a Season in a Cohort of Individuals Living or Working in a Long-term Care Facility
The Journal of Infectious Diseases. 228(4):383-390 [DOI] 10.1093/infdis/jiad029. [PMID] 36740584.
2023
Evidence of leaky protection following COVID-19 vaccination and SARS-CoV-2 infection in an incarcerated population
Nature Communications. 14(1) [DOI] 10.1038/s41467-023-40750-8. [PMID] 37598213.
2023
Household Transmission Dynamics of Seasonal Human Coronaviruses.
The Journal of infectious diseases. 227(9):1104-1112 [DOI] 10.1093/infdis/jiac436. [PMID] 36350773.
2023
Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.
The American journal of tropical medicine and hygiene. 109(2):413-419 [DOI] 10.4269/ajtmh.23-0091. [PMID] 37308104.
2023
Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness.
The Journal of infectious diseases. 227(5):663-674 [DOI] 10.1093/infdis/jiac453. [PMID] 36408616.
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
PLOS Medicine. 19(12) [DOI] 10.1371/journal.pmed.1004136. [PMID] 36454733.
2022
Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
BMJ (Clinical research ed.). 377 [DOI] 10.1136/bmj-2022-070102. [PMID] 35697361.
2022
Cost-effectiveness of monthly follow-up for the treatment of uncomplicated severe acute malnutrition: An economic evaluation of a randomized controlled trial.
PLOS global public health. 2(12) [DOI] 10.1371/journal.pgph.0001189. [PMID] 36962786.
2022
Effectiveness of a monthly schedule of follow-up for the treatment of uncomplicated severe acute malnutrition in Sokoto, Nigeria: A cluster randomized crossover trial
PLOS Medicine. 19(3) [DOI] 10.1371/journal.pmed.1003923. [PMID] 35231024.
2022
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Nature Communications. 13(1) [DOI] 10.1038/s41467-022-33169-0. [PMID] 36202800.
2022
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
The Lancet. Infectious diseases. 22(6):791-801 [DOI] 10.1016/S1473-3099(22)00140-2. [PMID] 35366959.
2022
EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil.
Trials. 23(1) [DOI] 10.1186/s13063-022-05997-4. [PMID] 35236394.
2022
Structural factors associated with SARS-CoV-2 infection risk in an urban slum setting in Salvador, Brazil: A cross-sectional survey
PLOS Medicine. 19(9) [DOI] 10.1371/journal.pmed.1004093. [PMID] 36074784.
2022
Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of COVID-19 Vaccine Effectiveness.
Epidemiology (Cambridge, Mass.). 33(4):450-456 [DOI] 10.1097/EDE.0000000000001484. [PMID] 35384900.
2021
Change in COVID-19 risk over time following vaccination with CoronaVac: A testnegative case-control study.
medRxiv : the preprint server for health sciences. [DOI] 10.1101/2021.12.23.21268335. [PMID] 34988559.
2021
Effect of specific non-pharmaceutical intervention policies on SARS-CoV-2 transmission in the counties of the United States.
Nature communications. 12(1) [DOI] 10.1038/s41467-021-23865-8. [PMID] 34117244.
2021
Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo
Nature Communications. 12(1) [DOI] 10.1038/s41467-021-26459-6. [PMID] 34711813.
2021
Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
The Lancet Regional Health – Americas. 1 [DOI] 10.1016/j.lana.2021.100025. [PMID] 34386791.
2021
Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.
BMJ (Clinical research ed.). 374 [DOI] 10.1136/bmj.n2015. [PMID] 34417194.
2021
Risk Factors for Healthcare Personnel Infection With Endemic Coronaviruses (HKU1, OC43, NL63, 229E): Results from the Respiratory Protection Effectiveness Clinical Trial (ResPECT).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 73(11):e4428-e4432 [DOI] 10.1093/cid/ciaa900. [PMID] 32645144.
2021
The Usefulness of the Test-Positive Proportion of Severe Acute Respiratory Syndrome Coronavirus 2 as a Surveillance Tool.
American journal of epidemiology. 190(7):1396-1405 [DOI] 10.1093/aje/kwab023. [PMID] 33576387.
2020
A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger.
Vaccine. 38(51):8161-8166 [DOI] 10.1016/j.vaccine.2020.10.079. [PMID] 33162202.
2020
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.
Nature communications. 11(1) [DOI] 10.1038/s41467-020-18450-4. [PMID] 32943637.
2020
Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
Vaccine. 38(46):7213-7216 [DOI] 10.1016/j.vaccine.2020.09.031. [PMID] 33012602.
2020
Humoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guinea.
Vaccine. 38(31):4877-4884 [DOI] 10.1016/j.vaccine.2020.04.066. [PMID] 32499066.
2019
Analysis of a meningococcal meningitis outbreak in Niger – potential effectiveness of reactive prophylaxis
PLOS Neglected Tropical Diseases. 13(3) [DOI] 10.1371/journal.pntd.0007077. [PMID] 30856166.
2019
Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection.
American journal of epidemiology. 188(2):467-474 [DOI] 10.1093/aje/kwy239. [PMID] 30329134.
2019
Linear growth faltering and the role of weight attainment: Prospective analysis of young children recovering from severe wasting in Niger
Maternal & Child Nutrition. 15(4) [DOI] 10.1111/mcn.12817. [PMID] 30903806.
2018
Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials.
American journal of epidemiology. 187(8):1763-1771 [DOI] 10.1093/aje/kwy047. [PMID] 29522080.
2018
Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials.
Clinical trials (London, England). 15(2):207-211 [DOI] 10.1177/1740774517752671. [PMID] 29374974.
2018
Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial
PLOS Medicine. 15(6) [DOI] 10.1371/journal.pmed.1002593. [PMID] 29944651.
2017
Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.
Trials. 18(1) [DOI] 10.1186/s13063-017-2028-y. [PMID] 28646924.
2017
Using simulation to aid trial design: Ring-vaccination trials.
PLoS neglected tropical diseases. 11(3) [DOI] 10.1371/journal.pntd.0005470. [PMID] 28328984.

Grants

Apr 2022 – Mar 2024
RAPID: Statistical inference of incidence of SARS-CoV-2 in the US using multiple data streams to identify levels of immunity and the impact of non-pharmaceutical interventions
Role: Co-Project Director/Principal Investigator
Funding: NATL SCIENCE FOU
Mar 2022 – Dec 2023
Estimating the incidence of dengue in travelers from non-endemic countries
Role: Co-Investigator
Funding: Merck Sharp & Dohme
Jan 2022 ACTIVE
IPA for Matthew Hitchings 2022
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Aug 2021 – Jul 2023
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Co-Investigator
Funding: EMORY UNIV via NATL INST OF HLTH NIAID
May 2020 ACTIVE
Forecasting trajectories of HIV transmission networks with a novel phylodynamic and deep learning framework
Role: Project Manager
Funding: NATL INST OF HLTH NIAID

Contact Details

Phones:
Business:
(352) 294-1945
Emails:
Business:
mhitchings@ufl.edu
Addresses:
Business Mailing:
PO BOX 117450
GAINESVILLE FL 326117450